Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Pancreatic Neoplasms 70Breast Neoplasms 64Neoplasms 35Carcinoma, Non-Small-Cell Lung 29Neoplasm Metastasis 20Triple Negative Breast Neoplasms 18Lung Neoplasms 13Ovarian Neoplasms 12Adenocarcinoma 12Stomach Neoplasms 10Squamous Cell Carcinoma of Head and Neck 10Melanoma 10Head and Neck Neoplasms 8Fallopian Tube Neoplasms 7Cholangiocarcinoma 7Urinary Bladder Neoplasms 6Recurrence 6Esophageal Neoplasms 6Parkinson Disease 4, Autosomal Dominant Lewy Body 5Digestive System Neoplasms 5Colorectal Neoplasms 5Carcinoma, Ovarian Epithelial 5Uterine Cervical Neoplasms 4Sarcoma, Ewing 4Sarcoma 4Prostatic Neoplasms 4Pancreatic Diseases 4Inflammatory Breast Neoplasms 4Gallbladder Neoplasms 4Endocrine Gland Neoplasms 4

Interventions

padeliporfin 4Nivolumab 4Gemcitabine 4Cyclophosphamide 4130-nm albumin-bound paclitaxel 4napabucasin 3Pemetrexed 3Fluorouracil 3Albumin-Bound Paclitaxel 3ficlatuzumab 2Trastuzumab 2Trabectedin 2Paclitaxel 2Leucovorin 2Irinotecan 2Bevacizumab 2sotorasib 1selinexor 1ribociclib 1relatlimab 1pralsetinib 1pembrolizumab 1pamiparib 1osimertinib 1nintedanib 1ipatasertib 1guadecitabine 1glutathione pegylated liposomal doxorubicin 1exemestane 1entinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Neoplasms by Site × Albumin-Bound Paclitaxel × Clear all
NCT02993731 2023-11-15

CanStem111P

Sumitomo Pharma America, Inc.

Phase 3 Completed
1,134 enrolled 18 charts
Gastrointestinal

Adenocarcinoma, Digestive System Diseases, Digestive System Neoplasms, Endocrine System Diseases, Endocrine Gland Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Pancreatic Diseases, Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal

NCT04299880 2023-11-08

Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols

Sumitomo Pharma America, Inc.

Phase 1 Completed
7 enrolled
Gastrointestinal

Adenocarcinoma, Digestive System Diseases, Digestive System Neoplasms, Neoplasms, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Pancreatic Neoplasms

NCT01964430 2023-06-28

apact

Celgene

Phase 3 Completed
866 enrolled 21 charts
Gastrointestinal

Adenocarcinoma, Digestive System Diseases, Digestive System Neoplasms, Endocrine System Diseases, Endocrine Gland Neoplasms, Neoplasms, Neoplasms by Site, Pancreatic Diseases, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡